A Bivalent Conjugate Vaccine for Malaria and Typhoid Prophylaxis

Malaria is the single leading cause of mortality, especially among children in the developing world. Typhoid fever, caused by infection with Salmonella typhi, is known to be endemic with malaria and causes its own significant disease burden. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response against Salmonella typhi Vi polysaccharide (ViP).

Potential Commercial Applications:		Competitive Advantages:
Development of this technology into a vaccine may protect vulnerable populations from both Malaria transmission and Typhoid fever.		This technology has significant advantages over current treatments, since there is currently only one commercial Malaria vaccine licensed for use in Europe only, which was not developed to address Malaria transmission, and the currently licensed Salmonella typhi vaccines show incomplete efficacy and do not provide long-term immunity. A formulation of the present technology has shown the ability to induce an immune response to Pfs25 in excess of 100 times higher and Salmonella typhi antigen 20-40 times higher than what is seen by immunization with either antigen alone.

Inventors:

Sojung An

Puthupparampil Scaria (NIAID)  ➽ more inventions...

Patrick Duffy (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. 62/327,184
PCT Application No. PCT/US17/029182

Collaboration Opportunity:
The National Institute of Allergy and Infectious Diseases, Laboratory of Malaria Immunology and Vaccinology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dr. Daniel Anacker at daniel.anacker@nih.gov or 301-761-7671.


Licensing Contact:
David (Po-Lung) Yang, Ph.D.
Email: polung.yang@nih.gov
Phone: 301-496-2644

OTT Reference No: E-124-2016-0
Updated: Mar 1, 2017